

REMARKS

The Examiner rejected claim 53, objected to claim 3, and allowed claim 6. Claims 3, 6 and 53 remain pending. As suggested by the Examiner, claims 3 and 53 have been amended herein to include sequence identifiers. In addition, claim 53 has been amended to remove the word "pharmaceutical" and replace the word "polypeptide" with the word "formulation." No new matter has been added.

In light of this amendment and the following remarks, Applicants respectfully request allowance of claims 3, 6, and 53.

Objections

The Examiner objected to claims 3 and 53 as not complying with 37 C.F.R. § 1.821(d). Claims 3 and 53 have been amended herein to include sequence identifiers.

In light of the above, Applicants respectfully request withdrawal of the objection to claims 3 and 53.

Rejections under 35 U.S.C. § 112, first paragraph

The Examiner rejected claim 53 under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the enablement requirement. Applicants respectfully disagree. To further prosecution, however, claim 53 has been amended herein as suggested by the Examiner.

In light of this amendment, Applicants respectfully request withdrawal of the rejection of claim 53 under 35 U.S.C. § 112, first paragraph.

CONCLUSION

Applicants submit that claims 3, 6, and 53 are in condition for allowance, which action is requested. The Examiner is invited to call the undersigned attorney at the telephone number


Applicant : John R. Riordan et al.
Serial No. : 10/030,585
Filed : May 22, 2002
Page : 4 of 4

Attorney's Docket No.: 07039-167002 / MMV-99-042

below if such will advance prosecution of this application. The Commissioner is authorized to charge any fees or credit any overpayments to Deposit Account No. 06-1050.

Respectfully submitted,

Date: July 28, 2006


J. Patrick Finn III, Ph.D.
Reg. No. 44,109

Fish & Richardson P.C.
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696

60372196.doc